[1] 陶雯琦, 刘颖斌. 晚期肝内胆管癌综合治疗研究进展[J]. 肿瘤, 2025, 45(3): 307-316.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA A Cancer J Clin, 2022, 72(1): 7-33. doi:  10.4324/9781003281900-16
[3] 王政禄, 丛文铭. 肝移植常见肝脏恶性肿瘤的病理分类及其临床特点[J]. 实用器官移植电子杂志, 2019, 7(2): 122-127.
[4] QURASHI M, VITHAYATHIL M, KHAN S A. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064. doi:  10.1016/j.ejso.2023.107064
[5] BANALES J M, CARDINALE V, CARPINO G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280. doi:  10.1038/nrgastro.2016.51
[6] AKATEH C, EJAZ A M, PAWLIK T M, et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma[J]. World J Hepatol, 2020, 12(10): 693-708. doi:  10.4254/wjh.v12.i10.693
[7] MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians[J]. CA A Cancer J Clin, 2023, 73(2): 198-222. doi:  10.3322/caac.21759
[8] CHANDRA P, SONG Y, DRILL E, et al. Intrahepatic cholangiocarcinoma: recurrence patterns, genomics, and survival[J]. JCO Precis Oncol, 2025, 9: e2500402.
[9] GUJARATHI R, PESHIN S, ZHANG X C, et al. Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel[J]. Hepatol Commun, 2025, 9(7): e0743. doi:  10.1097/hc9.0000000000000743
[10] 董志涛, 朱妍静, 钱尤雯, 等. 肝内胆管细胞癌类器官对吉西他滨联合顺铂化疗方案疗效预测价值研究[J]. 中国实用外科杂志, 2025, 45(8): 931-937,951. doi:  10.19538/j.cjps.issn1005-2208.2025.08.15
[11] 林圣哲, 张灵玉, 陶世莉, 等. 胆管癌类器官模型的构建及药物反应异质性的初步分析[J]. 中国肿瘤生物治疗杂志, 2025, 32(11): 1121-1127.
[12] DWYER B J, TIRNITZ-PARKER J E E. Patient-derived organoid models to decode liver pathophysiology[J]. Trends Endocrinol Metab, 2025, 36(3): 235-248. doi:  10.1016/j.tem.2024.07.019
[13] XU X, HUANG X F, XU W H. Marine actinomycetes-derived angucyclines and angucyclinones with biosynthesis and activity: past 10 years(2014–2023)[J]. Eur J Med Chem, 2025, 283: 117161. doi:  10.1016/j.ejmech.2024.117161
[14] 代影, 杨帆, 林厚文. 极地放线菌次级代谢产物及药理活性研究进展[J]. 天然产物研究与开发, 2023, 35(5): 901-913. doi:  10.16333/j.1001-6880.2023.5.018
[15] GIORDANO D, COPPOLA D, Russo R, et al. Marine microbial secondary metabolites: pathways, evolution and physiological roles[J]. Adv Microb Physiol, 2015, 66: 357-428.
[16] VLACHOGIANNIS G, HEDAYAT S, VATSIOU A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378): 920-926. doi:  10.1126/science.aao2774
[17] SELVARAJ B, WOON KIM D, PARK J S, et al. Neuroprotective effects of 2-heptyl-3-hydroxy-4-quinolone in HT22 mouse hippocampal neuronal cells[J]. Bioorg Med Chem Lett, 2021, 49: 128312. doi:  10.1016/j.bmcl.2021.128312
[18] NANDAKUMAR N, DANDELA R, GOPAS J, et al. Quorum sensing modulators exhibit cytotoxicity in Hodgkin’s lymphoma cells and interfere with NF-κB signaling[J]. Bioorg Med Chem Lett, 2017, 27(13): 2967-2973. doi:  10.1016/j.bmcl.2017.05.012
[19] JIA T Y, LI F M, LI T Z, et al. A Pseudomonas aeruginosa quorum-sensing metabolite manipulates macrophage ferroptosis through a methylation pathway[J]. Nat Commun, 2025, 16: 9992. doi:  10.1038/s41467-025-65142-y
[20] OGBECHI J, HUANG Y S, CLANCHY F I L, et al. Modulation of immune cell function, IDO expression and kynurenine production by the quorum sensor 2-heptyl-3-hydroxy-4-quinolone(PQS)[J]. Front Immunol, 2022, 13: 1001956. doi:  10.3389/fimmu.2022.1001956